earnings
confidence high
sentiment neutral
materiality 0.50
Zentalis reports Q2 2025 cash of $303.4M; DENALI Phase 2 on track for topline by end 2026
Zentalis Pharmaceuticals, Inc.
2025-Q2 EPS
reported -$1.05
vs consensus -$0.59
▼ miss
(-77.1%)
- Cash, cash equivalents and marketable securities $303.4M as of June 30, 2025; runway extended into late 2027.
- R&D expenses fell to $27.6M from $48.4M YoY; G&A expenses fell to $8.4M from $16.7M YoY.
- DENALI Phase 2 trial of azenosertib in Cyclin E1-positive PROC remains on track; topline data expected by year-end 2026.
- Strategic restructuring completed; no further non-recurring expenses expected.
- Part 2 data, if successful, could support accelerated approval subject to FDA feedback.